Cationic polymer coated mesoporous silica nanoparticles and uses thereof
A submicron structure having a silica body defining a plurality of pores is described. The submicron body may be spherical or non-spherical, and may include a cationic polymer or co-polymer on the surface of said silica body. The submicron structure may further include an oligonucleotide and be used to deliver the oligonucleotide to a cell. The submicron structure may further include a therapeutic agent and be used to deliver the therapeutic agent to a cell. An oligonucleotide and therapeutic agent may be used together. For example, when the oligonucleotide is an siRNA, the composition may be used to decrease cellular resistance to the therapeutic agent by decreasing translation of a resistance gene.
1. A dual delivery nanocarrier, comprising:
a silica body defining a plurality of pores and an outer surface between pore openings of said plurality of pores, where said silica body is functionalized with anionic surface groups;
a cationic polymer electrostatically bound to the surface of said silica body, wherein said cationic polymer does not occupy the interior of said pores;
an oligonucleotide bound to the cationic polymer wherein the oligonucleotide comprises an siRNA that reduces translation of protein causing drug resistance in a cell; and
an anti-cancer compound disposed within said plurality of pores, where said anti-cancer compound is cationic at physiological pH;
wherein said nanocarrier is effective to transfect a mammalian cancer cell and to increase drug sensitivity of said cancer cell, is non-toxic when administered in vivo in a mammal; and
said nanocarrier provides intracellular release of said anti-cancer compound in vivo.
2. The nanocarrier of claim 1 , wherein the siRNA reduces translation of p-glycoprotein.
3. The nanocarrier of claim 1 , wherein the anti-cancer compound comprises doxirubicin.
4. The nanocarrier of claim 1 , wherein the cationic polymer comprises a polymer selected from the group consisting of polyethyleneimine, polyamidoamine, polylysine, poly(allylamine), and poly(diallyldimethylammonium chloride).
5. The nanocarrier of claim 1 , wherein the cationic polymer comprises polyethyleneimine.
6. The nanocarrier of claim 1 , wherein the cationic polymer is a cationic co-polymer.
7. The nanocarrier of claim 1 , wherein the cationic co-polymer is a co-polymer of poly(ethyleneimine) and poly(ethylene glycol).
8. The nanocarrier of claim 1 , wherein said oligonucleotide is electrostatically bound to said cationic polymer.
9. The nanocarrier of claim 1 , wherein said siRNA comprises a duplex, where said duplex comprises the sense nucleotide sequence 5′-r(CGGAAGGCCUAAUGCCGAA)dTdT (SEQ ID NO: 1) and the antisense nucleotide sequence 5′-r(UUCGGCAUUAGGCCUUCCG)dG (SEQ ID NO:2).
10. The nanocarrier of claim 1 , wherein the silica body is mesoporous.
11. The nanocarrier of claim 1 , wherein the pores have an ensemble average diameter between about 1 nm and about 50 nm.
12. The nanocarrier of claim 1 , wherein said anionic surface groups comprise phosphonate moieties.
13. The nanocarrier of claim 1 , wherein said anionic surface groups comprise trihydroxysilylpropyl methylphosphonate.
14. The nanocarrier of claim 1 , further comprising a light-emitting compound, peptide, protein, oligonucleotide, sugar, oligosaccharide, or polysaccharide covalently bonded to the surface of the silica body.
15. The nanocarrier of claim 1 further comprising a core structure within said silica body.
16. The nanocarrier of claim 15 , wherein said core structure is a superparamagnetic nanocrystal, silver nanocrystal, or gold nanocrystal.
17. A method of treating a cancer, said method comprising administering to a subject in need thereof an effective amount of a nanocarrier of claim 1 .
18. The method of claim 17 , wherein said anti-cancer compound comprises doxirubicin.
19. The nanocarrier of claim 1 , wherein the pores are substantially cylindrical pores having an ensemble average diameter less than about 100 nm.
20. The nanocarrier of claim 2 , wherein the anti-cancer compound comprises doxirubicin.
21. The nanocarrier of claim 20 , wherein:
said anionic surface groups comprise a phosphonate; and
said cationic polymer comprises polyethylenimine (PEI).
22. The nanocarrier of claim 21 , wherein said siRNA comprises a duplex, where said duplex comprises the sense nucleotide sequence 5′-r(CGGAAGGCCUAAUGCCGAA)dTdT (SEQ ID NO: 1) and the antisense nucleotide sequence 5′-r(UUCGGCAUUAGGCCUUCCG)dG (SEQ ID NO:2).
23. The nanocarrier of claim 22 , wherein the pores are substantially cylindrical pores having an ensemble average diameter between about 1 nm and about 10 nm.